Indivior: SUBLOCADE Reduces Relapse Risk, Healthcare Use in OUD

Indivior Pharmaceuticals announced findings from two new real-world evidence studies on SUBLOCADE® (extended-release buprenorphine) for opioid use disorder (OUD). The studies showed that adherence to monthly injectable buprenorphine is associated with a significantly lower relapse risk, fewer infection-related complications, and reduced healthcare utilization. Patients on SUBLOCADE were 3.5 to 8.1 times less likely to return to opioid use and experienced a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits compared to other MOUD treatments. These findings highlight the benefits of sustained treatment and the potential to reduce costly acute care crises.